Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Accumulated Expenses (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Accumulated Expenses for 5 consecutive years, with $9.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Expenses fell 8.92% to $9.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $9.0 million, a 8.92% decrease, with the full-year FY2024 number at $10.6 million, up 19.5% from a year prior.
  • Accumulated Expenses was $9.0 million for Q3 2025 at Werewolf Therapeutics, up from $8.5 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $14.2 million in Q4 2022 to a low of $2.9 million in Q1 2021.
  • A 5-year average of $9.1 million and a median of $8.9 million in 2023 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: surged 307.7% in 2022, then plummeted 53.34% in 2024.
  • Werewolf Therapeutics' Accumulated Expenses stood at $8.8 million in 2021, then skyrocketed by 61.46% to $14.2 million in 2022, then plummeted by 37.39% to $8.9 million in 2023, then rose by 19.5% to $10.6 million in 2024, then decreased by 14.8% to $9.0 million in 2025.
  • Per Business Quant, the three most recent readings for HOWL's Accumulated Expenses are $9.0 million (Q3 2025), $8.5 million (Q2 2025), and $9.3 million (Q1 2025).